Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells1

The mechanism of tumor-associated T cell dysfunction remains an unresolved problem of tumor immunology. Development of T cell defects in tumor-bearing hosts are often associated with increased production of immature myeloid cells. In tumor-bearing mice, these immature myeloid cells are represented by a population of Gr-1+ cells. In this study we investigated an effect of these cells on T cell function. Gr-1+ cells were isolated from MethA sarcoma or C3 tumor-bearing mice using cell sorting. These Gr-1+ cells expressed myeloid cell marker CD11b and MHC class I molecules, but they lacked expression of MHC class II molecules. Tumor-induced Gr-1+ cells did not affect T cell responses to Con A and to a peptide presented by MHC class II. In sharp contrast, Gr-1+ cells completely blocked T cell response to a peptide presented by MHC class I in vitro and in vivo. Block of the specific MHC class I molecules on the surface of Gr-1+ cells completely abrogated the observed effects of these cells. Thus, immature myeloid cells specifically inhibited CD8-mediated Ag-specific T cell response, but not CD4-mediated T cell response. Differentiation of Gr-1+ cells in the presence of growth factors and all-trans retinoic acid completely eliminated inhibitory potential of these cells. This may suggest a new approach to cancer treatment.

[1]  Larry R. Smith,et al.  Defined Flanking Spacers and Enhanced Proteolysis Is Essential for Eradication of Established Tumors by an Epitope String DNA Vaccine1 , 2001, The Journal of Immunology.

[2]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.

[3]  Shu-Hsia Chen,et al.  Gr-1+ Myeloid Cells Derived from Tumor-Bearing Mice Inhibit Primary T Cell Activation Induced Through CD3/CD28 Costimulation1 , 2000, The Journal of Immunology.

[4]  D. Carbone,et al.  Clinical significance of defective dendritic cell differentiation in cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  J. Allison,et al.  In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  P. Opolon,et al.  Nitric oxide mediation of active immunosuppression associated with graft-versus-host reaction. , 1999, Blood.

[7]  H. Bien,et al.  Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40 , 1999, Nature Medicine.

[8]  J. Miyauchi All-trans retinoic acid and hematopoietic growth factors regulating the growth and differentiation of blast progenitors in acute promyelocytic leukemia. , 1999, Leukemia & lymphoma.

[9]  H. Etlinger,et al.  the Journal of Immunology , 2006 .

[10]  D. Carbone,et al.  Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. , 1998, Blood.

[11]  S. Rosenberg,et al.  Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. , 1998, Journal of immunology.

[12]  M. Young,et al.  Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas. , 1997, Journal of immunology.

[13]  D. Carbone,et al.  Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. , 1997, Human gene therapy.

[14]  尾辻瑞人 Oxidative stress by tumor-derived macrophages suppresses the expression of CD 3 ζ chain of T cell receptor complex and antigen-specific T cell responses(担癌状態のマクロファージによる酸化ストレスに基づくT細胞受容体の構造異常と機能抑制) , 1997 .

[15]  C. Nathan,et al.  Nitric oxide and macrophage function. , 1997, Annual review of immunology.

[16]  T. Saito,et al.  Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Carbone,et al.  IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[18]  M. Young,et al.  Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide. , 1996, Journal of immunology.

[19]  D. Lopez,et al.  Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses. , 1995, Journal of immunology.

[20]  S. H. van der Burg,et al.  Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16‐induced tumors , 1995, European journal of immunology.

[21]  I. Angulo,et al.  Involvement of nitric oxide in bone marrow-derived natural suppressor activity. Its dependence on IFN-gamma. , 1995, Journal of immunology.

[22]  H. Dombret,et al.  All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. , 1995, Blood.

[23]  Yao-Tseng Chen,et al.  Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  B. Gansbacher,et al.  Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2-secreting tumors. , 1994, Journal of immunology.

[25]  A. Rolink,et al.  Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor , 1994, The Journal of experimental medicine.

[26]  L. Old,et al.  A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Minden,et al.  Modulation of Growth Factor Receptors on Acute Myeloblastic Leukemia Cells by Retinoic Acid , 1994, Japanese journal of cancer research : Gann.

[28]  M. Feltkamp,et al.  Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells , 1993, European journal of immunology.

[29]  C. Chomienne,et al.  Retinoid acid supports granulocytic but not erythroid differentiation of myeloid progenitors in normal bone marrow cells. , 1993, Leukemia.

[30]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  T. Whiteside,et al.  T cell recognition of human tumors: implications for molecular immunotherapy of cancer. , 1993, Clinical immunology and immunopathology.

[32]  D. Sulitzeanu Immunosuppressive factors in human cancer. , 1993, Advances in cancer research.

[33]  E. Besa Acute promyelocytic leukemia. , 1991, Blood.

[34]  H. Kantarjian,et al.  Detection of leukemic clone maturation in vivo by premature chromosome condensation. , 1988, Blood.

[35]  M. Young,et al.  Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. , 1987, Cancer research.

[36]  S. Collins,et al.  Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. , 1981, Blood.